Compare BCPC & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | INDV |
|---|---|---|
| Founded | 1967 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.7B |
| IPO Year | 1995 | 2014 |
| Metric | BCPC | INDV |
|---|---|---|
| Price | $160.13 | $37.81 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $176.00 | N/A |
| AVG Volume (30 Days) | 163.3K | ★ 2.0M |
| Earning Date | 04-30-2026 | 06-08-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | 20.87 | ★ 8100.00 |
| EPS | ★ 1.25 | 0.69 |
| Revenue | $799,023,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $128.96 | ★ $54.70 |
| Revenue Growth | ★ 13.56 | 4.29 |
| 52 Week Low | $139.17 | $11.08 |
| 52 Week High | $183.90 | $41.00 |
| Indicator | BCPC | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 40.23 | 58.90 |
| Support Level | $159.00 | $29.71 |
| Resistance Level | $165.24 | $37.83 |
| Average True Range (ATR) | 3.58 | 1.36 |
| MACD | -0.10 | -0.32 |
| Stochastic Oscillator | 47.00 | 37.98 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).